Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia

This study has been completed.
Information provided by:
National Center for Complementary and Integrative Health (NCCIH) Identifier:
First received: August 18, 2003
Last updated: April 21, 2008
Last verified: April 2008
The purpose of this study is to determine if intravenous micronutrient therapy (IVMT) is effective in the treatment of fibromyalgia, as assessed by validated functional and pain measures.

Condition Intervention Phase
Drug: Intravenous micronutrient therapy
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia

Resource links provided by NLM:

Further study details as provided by National Center for Complementary and Integrative Health (NCCIH):

Estimated Enrollment: 40
Study Start Date: June 2004
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Detailed Description:
As per Brief Summary

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Meet the American College of Rheumatology criteria for Fibromyalgia diagnosis;
  • On no medication for Fibromyalgia other than acetaminophen, or willing to stop all such medication for the duration of the study

    • Willing to stop all FMS medication for the duration of the study or be on a stable dose of such medication for at least 3 months

Exclusion criteria:

  • Other concurrent medical conditions such as rheumatologic disease, chronic infection, untreated endocrine disorders, unstable seizures, psychiatric disorders, acute peptic ulcer disease, congestive heart failure, chronic liver disorders and/or bleeding problems

    • Allergy to thiamin
  • Unwilling to stop vitamin supplementation for the duration of the study

    • PLEASE NOTE: Travel to and accomodations at the study site can NOT be compensated. Anyone wishing to travel from outside of the study site's geographic area must do so at their own risk and expense.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00067405

United States, Connecticut
Yale-Griffin Prevention Research Center
Derby, Connecticut, United States, 06418
Sponsors and Collaborators
National Center for Complementary and Integrative Health (NCCIH)
Principal Investigator: David Katz, MD Yale-Griffin Prevention Research Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00067405     History of Changes
Other Study ID Numbers: R21AT000942-01A1 ( US NIH Grant/Contract Award Number )
Study First Received: August 18, 2003
Last Updated: April 21, 2008

Keywords provided by National Center for Complementary and Integrative Health (NCCIH):
Intravenous micronutrient therapy
alternative medicine
complementary medicine
vitamin supplements

Additional relevant MeSH terms:
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases
Trace Elements
Growth Substances
Physiological Effects of Drugs processed this record on May 25, 2017